Modulation of the constitutive activity of the ghrelin receptor by use of pharmacological tools and mutagenesis

Methods in Enzymology

Volumn 484, Issue C, 2010, Pages 53-73

  Mokrosiński, Jacek ^a   Holst, Birgitte ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; CALCIUM ION; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIACYLGLYCEROL; GHRELIN RECEPTOR; GHRELIN RECEPTOR 1A; GHRELIN RECEPTOR 1B; GHRELIN RECEPTOR AGONIST; GHRELIN RECEPTOR ANTAGONIST; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; INOSITOL 1,4,5 TRISPHOSPHATE; INOSITOL MONOPHOSPHATASE; INOSITOL PHOSPHATE; LITHIUM ION; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOAMINE; MUTANT PROTEIN; NEUROTENSIN RECEPTOR; PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PHOSPHOLIPASE C; SUBSTANCE P [1 DEXTRO ARGININE 5 DEXTRO PHENYLALANINE 7,9 DEXTRO TRYPTOPHAN 11 LEUCINE]; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; APPETITE; BOOK; DEPHOSPHORYLATION; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; ENERGY EXPENDITURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE LOCUS; GENE MUTATION; GENETIC VARIABILITY; GROWTH HORMONE RELEASE; HUMAN; INVERSE AGONISM; LIPID STORAGE; MOLECULAR WEIGHT; MUTAGENESIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN MOTIF; PROTEIN STRUCTURE; RECEPTOR BINDING; REPORTER GENE; SIGNAL TRANSDUCTION;

EID: 78049237699     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381298-8.00003-4     Document Type: Chapter

References (66)

1. Abizaid A., Liu Z.W., Andrews Z.B., Shanabrough M., Borok E., Elsworth J.D., Roth R.H., Sleeman M.W., Picciotto M.R., Tschop M.H., Gao X.B., Horvath T.L. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J. Clin. Invest. 2006, 116:3229-3239.
2. Ahuja S., Smith S.O. Multiple switches in G protein-coupled receptor activation. Trends Pharmacol. Sci. 2009, 30:494-502.
3. Ahuja S., Hornak V., Yan E.C., Syrett N., Goncalves J.A., Hirshfeld A., Ziliox M., Sakmar T.P., Sheves M., Reeves P.J., Smith S.O., Eilers M. Helix movement is coupled to displacement of the second extracellular loop in rhodopsin activation. Nat. Struct. Mol. Biol. 2009, 16:168-175.
4. Ariyasu H., Takaya K., Tagami T., Ogawa Y., Hosoda K., Akamizu T., Suda M., Koh T., Natsui K., Toyooka S., Shirakami G., Usui T., et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol. Metab. 2001, 86:4753-4758.
5. Bach M.A., Rockwood K., Zetterberg C., Thamsborg G., Hebert R., Devogelaer J.P., Christiansen J.S., Rizzoli R., Ochsner J.L., Beisaw N., Gluck O., Yu L., et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J. Am. Geriatr. Soc. 2004, 52:516-523.
6. Ballesteros J.A., Shi L., Javitch J.A. Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 2001, 60:1-19.
7. Bokoch M.P., Zou Y., Rasmussen S.G., Liu C.W., Nygaard R., Rosenbaum D.M., Fung J.J., Choi H.J., Thian F.S., Kobilka T.S., Puglisi J.D., Weis W.I., et al. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010, 463:108-112.
8. Bowers C.Y., Momany F.A., Reynolds G.A., Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984, 114:1537-1545.
9. Costa T., Cotecchia S. Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors. Trends Pharmacol. Sci. 2005, 26:618-624.
10. Davenport A.P., Bonner T.I., Foord S.M., Harmar A.J., Neubig R.R., Pin J.P., Spedding M., Kojima M., Kangawa K. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol. Rev. 2005, 57:541-546.
11. Diano S., Farr S.A., Benoit S.C., McNay E.C., da Silva I., Horvath B., Gaskin F.S., Nonaka N., Jaeger L.B., Banks W.A., Morley J.E., Pinto S., et al. Ghrelin controls hippocampal spine synapse density and memory performance. Nat. Neurosci. 2006, 9:381-388.
12. Dror R.O., Arlow D.H., Borhani D.W., Jensen M.O., Piana S., Shaw D.E. Identification of two distinct inactive conformations of the beta2-adrenergic receptor reconciles structural and biochemical observations. Proc. Natl. Acad. Sci. USA 2009, 106:4689-4694.
13. Einat H., Kofman O., Itkin O., Lewitan R.J., Belmaker R.H. Augmentation of lithium's behavioral effect by inositol uptake inhibitors. J. Neural Transm. 1998, 105:31-38.
14. Elling C.E., Frimurer T.M., Gerlach L.O., Jorgensen R., Holst B., Schwartz T.W. Metal ion site engineering indicates a global toggle switch model for seven-transmembrane receptor activation. J. Biol. Chem. 2006, 281:17337-17346.
15. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 2000, 21:90-113.
16. Gether U., Lin S., Kobilka B.K. Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J. Biol. Chem. 1995, 270:28268-28275.
17. Gether U., Ballesteros J.A., Seifert R., Sanders-Bush E., Weinstein H., Kobilka B.K. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J. Biol. Chem. 1997, 272:2587-2590.
18. Goodyear S., Arasaradnam R.P., Quraishi N., Mottershead M., Nwokolo C.U. Acylated and des acyl ghrelin in human portal and systemic circulations. Mol. Biol. Rep 2010, (Epub ahead of print).
19. Graaf de C., Rognan D. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. J. Med. Chem. 2008, 51:4978-4985.
20. Granata R., Settanni F., Biancone L., Trovato L., Nano R., Bertuzzi F., Destefanis S., Annunziata M., Martinetti M., Catapano F., Ghe C., Isgaard J., et al. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: Involvement of 3',5'-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-Kinase/Akt signaling. Endocrinology 2007, 148:512-529.
21. Hansen B.S., Raun K., Nielsen K.K., Johansen P.B., Hansen T.K., Peschke B., Lau J., Andersen P.H., Ankersen M. Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur. J. Endocrinol. 1999, 141:180-189.
22. Hewson A.K., Tung L.Y., Connell D.W., Tookman L., Dickson S.L. The rat arcuate nucleus integrates peripheral signals provided by leptin, insulin, and a ghrelin mimetic. Diabetes 2002, 51:3412-3419.
23. Holst B., Schwartz T.W. Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends Pharmacol. Sci. 2004, 25:113-117.
24. Holst B., Schwartz T.W. Ghrelin receptor mutations-Too little height and too much hunger. J. Clin. Invest. 2006, 116:637-641.
25. Holst B., Cygankiewicz A., Jensen T.H., Ankersen M., Schwartz T.W. High constitutive signaling of the ghrelin receptor-Identification of a potent inverse agonist. Mol. Endocrinol. 2003, 17:2201-2210.
26. Holst B., Holliday N.D., Bach A., Elling C.E., Cox H.M., Schwartz T.W. Common structural basis for constitutive activity of the ghrelin receptor family. J. Biol. Chem. 2004, 279:53806-53817.
27. Holst B., Lang M., Brandt E., Bach A., Howard A., Frimurer T.M., Beck-Sickinger A., Schwartz T.W. Ghrelin receptor inverse agonists: Identification of an active peptide core and its interaction epitopes on the receptor. Mol. Pharmacol. 2006, 70:936-946.
28. Holst B., Mokrosinski J., Lang M., Brandt E., Nygaard R., Frimurer T.M., Beck-Sickinger A.G., Schwartz T.W. Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J. Biol. Chem. 2007, 282:15799-15811.
29. Holst B., Nygaard R., Valentin-Hansen L., Bach A., Engelstoft M.S., Petersen P.S., Frimurer T.M., Schwartz T.W. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. J. Biol. Chem. 2010, 285:3973-3985.
30. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., Hamelin M., Hreniuk D.L., Palyha O.C., Anderson J., Paress P.S., Diaz C., et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273:974-977.
31. Hubbell W.L., Altenbach C., Hubbell C.M., Khorana H.G. Rhodopsin structure, dynamics, and activation: A perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv. Protein Chem. 2003, 63:243-290.
32. Javitch J.A., Fu D., Liapakis G., Chen J. Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J. Biol. Chem. 1997, 272:18546-18549.
33. Jerlhag E., Egecioglu E., Landgren S., Salome N., Heilig M., Moechars D., Datta R., Perrissoud D., Dickson S.L., Engel J.A. Requirement of central ghrelin signaling for alcohol reward. Proc. Natl. Acad. Sci. USA 2009, 106:11318-11323.
34. Katritch V., Reynolds K.A., Cherezov V., Hanson M.A., Roth C.B., Yeager M., Abagyan R. Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. J. Mol. Recognit. 2009, 22:307-318.
35. Kirchner H., Gutierrez J.A., Solenberg P.J., Pfluger P.T., Czyzyk T.A., Willency J.A., Schurmann A., Joost H.G., Jandacek R.J., Hale J.E., Heiman M.L., Tschop M.H. GOAT links dietary lipids with the endocrine control of energy balance. Nat. Med. 2009, 15:741-745.
36. Kojima M., Kangawa K. Ghrelin: Structure and function. Physiol. Rev. 2005, 85:495-522.
37. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
38. Kojima M., Hosoda H., Matsuo H., Kangawa K. Ghrelin: Discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol. Metab. 2001, 12:118-122.
39. Korbonits M., Goldstone A.P., Gueorguiev M., Grossman A.B. Ghrelin-A hormone with multiple functions. Front. Neuroendocrinol. 2004, 25:27-68.
40. Leung P.K., Chow K.B., Lau P.N., Chu K.M., Chan C.B., Cheng C.H., Wise H. The truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the ghrelin receptor. Cell. Signal. 2007, 19:1011-1022.
41. Lopez M., Lage R., Saha A.K., Perez-Tilve D., Vazquez M.J., Varela L., Sangiao-Alvarellos S., Tovar S., Raghay K., Rodriguez-Cuenca S., Deoliveira R.M., Castaneda T., et al. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. 2008, 7:389-399.
42. Matthews R.P., Guthrie C.R., Wailes L.M., Zhao X., Means A.R., McKnight G.S. Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate CREB-dependent gene expression. Mol. Cell. Biol. 1994, 14:6107-6116.
43. Mirzadegan T., Benko G., Filipek S., Palczewski K. Sequence analyses of G-protein-coupled receptors: Similarities to rhodopsin. Biochemistry 2003, 42:2759-2767.
44. Murphy M.G., Weiss S., McClung M., Schnitzer T., Cerchio K., Connor J., Krupa D., Gertz B.J. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. 2001, 86:1116-1125.
45. Nogueiras R., Tovar S., Mitchell S.E., Rayner D.V., Archer Z.A., Dieguez C., Williams L.M. Regulation of growth hormone secretagogue receptor gene expression in the arcuate nuclei of the rat by leptin and ghrelin. Diabetes 2004, 53:2552-2558.
46. Nygaard R., Frimurer T.M., Holst B., Rosenkilde M.M., Schwartz T.W. Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol. Sci. 2009, 30:249-259.
47. Pantel J., Legendre M., Cabrol S., Hilal L., Hajaji Y., Morisset S., Nivot S., Vie-Luton M.P., Grouselle D., de Kerdanet M., Kadiri A., Epelbaum J., et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J. Clin. Invest. 2006, 116:760-768.
48. Patchett A.A., Nargund R.P., Tata J.R., Chen M.H., Barakat K.J., Johnston D.B., Cheng K., Chan W.W., Butler B., Hickey G., Jacks T., Schleim K., et al. Design and biological activities of L-163, 191 (MK-0677): A potent, orally active growth hormone secretagogue. Proc. Natl. Acad. Sci. USA 1995, 92:7001-7005.
49. Perello M., Sakata I., Birnbaum S., Chuang J.C., Osborne-Lawrence S., Rovinsky S.A., Woloszyn J., Yanagisawa M., Lutter M., Zigman J.M. Ghrelin increases the rewarding value of high-fat diet in an orexin-dependent manner. Biol. Psychiatry 2010, 67:880-886.
50. Petersen P.S., Woldbye D.P., Madsen A.N., Egerod K.L., Jin C., Lang M., Rasmussen M., Beck-Sickinger A.G., Holst B. In vivo characterization of high Basal signaling from the ghrelin receptor. Endocrinology 2009, 150:4920-4930.
51. Rasmussen S.G., Jensen A.D., Liapakis G., Ghanouni P., Javitch J.A., Gether U. Mutation of a highly conserved aspartic acid in the beta2 adrenergic receptor: Constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. Mol. Pharmacol. 1999, 56:175-184.
52. Samama P., Cotecchia S., Costa T., Lefkowitz R.J. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 1993, 268:4625-4636.
53. Scheerer P., Park J.H., Hildebrand P.W., Kim Y.J., Krauss N., Choe H.W., Hofmann K.P., Ernst O.P. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008, 455:497-502.
54. Schwartz T.W., Frimurer T.M., Holst B., Rosenkilde M.M., Elling C.E. Molecular mechanism of 7TM receptor activation-A global toggle switch model. Annu. Rev. Pharmacol. Toxicol. 2006, 46:481-519.
55. Seifert R., Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: Cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2002, 366:381-416.
56. Shi L., Liapakis G., Xu R., Guarnieri F., Ballesteros J.A., Javitch J.A. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 2002, 277:40989-40996.
57. Singh L.P., Andy J., Anyamale V., Greene K., Alexander M., Crook E.D. Hexosamine-induced fibronectin protein synthesis in mesangial cells is associated with increases in cAMP responsive element binding (CREB) phosphorylation and nuclear CREB: The involvement of protein kinases A and C. Diabetes 2001, 50:2355-2362.
58. Smit M.J., Vischer H.F., Bakker R.A., Jongejan A., Timmerman H., Pardo L., Leurs R. Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. Annu. Rev. Pharmacol. Toxicol. 2007, 47:53-87.
59. Swaminath G., Xiang Y., Lee T.W., Steenhuis J., Parnot C., Kobilka B.K. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J. Biol. Chem. 2004, 279:686-691.
60. Swaminath G., Deupi X., Lee T.W., Zhu W., Thian F.S., Kobilka T.S., Kobilka B. Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J. Biol. Chem. 2005, 280:22165-22171.
61. Theander-Carrillo C., Wiedmer P., Cettour-Rose P., Nogueiras R., Perez-Tilve D., Pfluger P., Castaneda T.R., Muzzin P., Schurmann A., Szanto I., Tschop M.H., Rohner-Jeanrenaud F. Ghrelin action in the brain controls adipocyte metabolism. J. Clin. Invest. 2006, 116:1983-1993.
62. Tschop M., Smiley D.L., Heiman M.L. Ghrelin induces adiposity in rodents. Nature 2000, 407:908-913.
63. Vanni S., Neri M., Tavernelli I., Rothlisberger U. Observation of "ionic lock" formation in molecular dynamics simulations of wild-type beta 1 and beta 2 adrenergic receptors. Biochemistry 2009, 48:4789-4797.
64. Yang J., Brown M.S., Liang G., Grishin N.V., Goldstein J.L. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008, 132:387-396.
65. Yao X.J., Velez R.G., Whorton M.R., Rasmussen S.G., Devree B.T., Deupi X., Sunahara R.K., Kobilka B. The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc. Natl. Acad. Sci. USA 2009, 106:9501-9506.
66. Zhang W., Chai B., Li J.Y., Wang H., Mulholland M.W. Effect of des-acyl ghrelin on adiposity and glucose metabolism. Endocrinology 2008, 149:4710-4716.